| Literature DB >> 26042206 |
Kommoju Uma Jyothi1, Battini Mohan Reddy1.
Abstract
Fifteen SNPs from nine different genes were genotyped on 1379 individuals, 758 T2DM patients and 621 controls, from the city of Hyderabad, India, using Sequenom Massarray platform. These data were analyzed to examine the role of gene-gene and gene-environment interactions in the manifestation of T2DM. The multivariate analysis suggests that TCF7L2, CDKAL1, IGF2BP2, HHEX and PPARG genes are significantly associated with T2DM, albeit only the first two of the above 5 were associated in the univariate analysis. Significant gene-gene and gene-environment interactions were also observed with reference to TCF7L2, CAPN10 and CDKAL1 genes, highlighting their importance in the pathophysiology of T2DM. In the analysis for cumulative effect of risk alleles, SLC30A8 steps in as significant contributor to the disease by its presence in all combinations of risk alleles. A striking difference between risk allele categories, 1-4 and 5-6, was evident in showing protective and susceptible roles, respectively, while the latter was characterized by the presence of TCF7L2 and CDKAL1 variants. Overall, these two genes TCF7L2 and CDKAL1 showed strong association with T2DM, either individually or in interaction with the other genes. However, we need further studies on gene-gene and gene-environment interactions among heterogeneous Indian populations to obtain unequivocal conclusions that are applicable for the Indian population as a whole.Entities:
Keywords: Gene–environment interactions; Gene–gene interactions; India; Population of Hyderabad; Type 2 diabetes mellitus
Year: 2015 PMID: 26042206 PMCID: PMC4443428 DOI: 10.1016/j.mgene.2015.05.001
Source DB: PubMed Journal: Meta Gene ISSN: 2214-5400
Multivariate logistic regression analysis of alleles and genotypes of T2DM cases and controls with and without using covariates.
| SNP | Allele | Adjusted for covariates | Genotype | Adjusted for covariates | |||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95%C.I. | p-Value | OR | 95%C.I. | p-Value | ||||
| rs7903146 | T | 2.02 | 1.61–2.52 | < | CT | 1.99 | 1.49–2.64 | < | |
| TT | 3.58 | 2.09–6.13 | < | ||||||
| rs1470579 | C | 1.31 | 1.07–1.61 | CA | 1.27 | 0.91–1.76 | 0.161 | ||
| CC | 1.22 | 0.83–1.78 | 0.312 | ||||||
| rs13266634 | C | 1.19 | 0.94–1.51 | 0.156 | CT | 1.09 | 0.56–2.11 | 0.799 | |
| CC | 1.1 | 0.57–2.10 | 0.777 | ||||||
| rs7756992 | G | 1.3 | 1.03–1.64 | AG | 1.3 | 0.98–1.73 | |||
| GG | 1.97 | 1.09–3.56 | |||||||
| rs10811661 | T | 1.2 | 0.91–1.59 | 0.188 | CT | 0.64 | 0.21–1.97 | 0.433 | |
| TT | 0.95 | 0.31–2.87 | 0.927 | ||||||
| rs1111875 | G | 0.79 | 0.65–0.98 | AG | 1.11 | 0.81–1.51 | 0.516 | ||
| GG | 0.88 | 0.59–1.30 | 0.52 | ||||||
| rs1801278 | A | 1.21 | 0.74–1.99 | 0.45 | AA | 1.46 | 0.12–18.01 | 0.77 | |
| GA | 1.45 | 0.85–2.47 | 0.175 | ||||||
| rs3792267 | A | 1.81 | 0.89–1.56 | 0.242 | AA | 1.58 | 0.66–3.77 | 0.307 | |
| GA | 1.27 | 0.92–1.74 | 0.147 | ||||||
| rs1801282 | C | 1.14 | 0.84–1.54 | 0.413 | GC | 0.7 | 0.50–0.99 | ||
| GG | 1.22 | 0.41–3.59 | 0.721 | ||||||
| Age | 0.99 | 0.98–1.00 | 0.069 | 0.99 | 0.97–1.01 | 0.217 | |||
| Gender | 0.74 | 0.58–0.94 | 0.7 | 0.50–0.99 | |||||
| Migration | 0.45 | 0.37–0.55 | 0.44 | 0.33–0.58 | |||||
| V/NV | 0.67 | 0.52–0.85 | 0.68 | 0.48–0.97 | |||||
| Junk food | 1.41 | 1.14–1.75 | 1.36 | 0.99–1.86 | |||||
| Alcohol | 1.1 | 0.86–1.40 | 0.44 | 1.13 | 0.8–1.66 | 0.497 | |||
| Smoking | 0.68 | 0.51–0.90 | 0.65 | 0.43–0.99 | |||||
| Physical activity | 1.19 | 1.06–1.33 | 1.18 | 1.0–1.4 | |||||
| BMI | 1.16 | 1.13–1.19 | 1.16 | 1.12–1.2 | |||||
Gene name — Abbreviation: Transcription factor 7 like 2 — TCF7L2, insulin growth factor2 mRNA binding protein 2 — IGF2BP2, solute carrier (Zinc transporter) 30 member 8 — SLC30A8, CDK5 regulatory subunit associated protein 1 — like 1 — CDKAL1, Cyclin-dependent kinase inhibitor 2A/B — CDKN2A/B, Hematopoietically expressed homeo box gene — HHEX, Insulin receptor substrate1—IRS1, Calcium activated cysteine protease — CAPN10, Peroxisome proliferator activated receptor gamma—PPARG.
5% and 10% significance was considered.
Odds ratio calculated with respect to risk allele.
Significant p values bolded.
Pair-wise gene–gene interaction analysis using logistic regression.
| Gene–gene | SNP–SNP | OR | p value |
|---|---|---|---|
| rs1801278–rs3792267 | 0.8191 | 0.6768 | |
| rs1801278–rs1801282 | 0.8852 | 0.7425 | |
| rs1801278–rs1470579 | 0.6701 | 0.2194 | |
| rs1801278–rs7756992 | 0.7329 | 0.3829 | |
| rs1801278–rs13266634 | 0.4999 | 0.1207 | |
| rs1801278–rs10811661 | 1.676 | 0.2796 | |
| rs1801278–rs1111875 | 1.691 | 0.1382 | |
| rs1801278–rs7903146 | 0.6869 | 0.2722 | |
| rs3792267–rs1801282 | 1.053 | 0.8523 | |
| rs3792267–rs1470579 | 0.9752 | 0.879 | |
| rs3792267–rs13266634 | 0.8354 | 0.3714 | |
| rs3792267–rs10811661 | 0.705 | 0.1837 | |
| rs3792267–rs1111875 | 0.8798 | 0.4466 | |
| rs1801282–rs1470579 | 1.27 | 0.212 | |
| rs1801282–rs7756992 | 1.017 | 0.936 | |
| rs1801282–rs13266634 | 1.006 | 0.9785 | |
| rs1801282–rs10811661 | 1.051 | 0.8517 | |
| rs1801282–rs1111875 | 1.262 | 0.2174 | |
| rs1801282–rs7903146 | 0.9236 | 0.7022 | |
| rs1470579–rs7756992 | 0.8414 | 0.2244 | |
| rs1470579–rs13266634 | 0.8659 | 0.315 | |
| rs1470579–rs10811661 | 1.177 | 0.3708 | |
| rs1470579–rs1111875 | 1.081 | 0.5149 | |
| rs1470579–rs7903146 | 0.9879 | 0.9337 | |
| rs7756992–rs13266634 | 1.171 | 0.3507 | |
| rs7756992–rs10811661 | 1.005 | 0.9796 | |
| rs7756992–rs1111875 | 1.148 | 0.3382 | |
| rs7756992–rs7903146 | 1.023 | 0.8892 | |
| rs13266634–rs10811661 | 0.8075 | 0.3433 | |
| rs13266634–rs1111875 | 0.9575 | 0.7633 | |
| rs13266634–rs7903146 | 0.8404 | 0.3244 | |
| rs10811661–rs1111875 | 1.114 | 0.5285 | |
| rs10811661–rs7903146 | 0.9969 | 0.988 | |
| rs1111875–rs7903146 | 1.016 | 0.9072 |
Results presented according to the ascending order of chromosomal location.
Significant p values bolded — 5% and 10% significance was considered.
Summary table of best gene–gene interaction models using GMDR with and without adjusting for covariates.
| Combination | Unadjusted for covariates | Adjusted for covariates | ||||||
|---|---|---|---|---|---|---|---|---|
| Bal.Acc.CV training | Bal.Acc.CV testing | CVC consistency | Sign test (p) | Bal.Acc.CV training | Bal.Acc.CV testing | CVC consistency | Sign test (p) | |
| 0.5936 | 0.5952 | 10/10 | 10 (0.0010) | 0.5972 | 0.5979 | 10/10 | 10 (0.0010) | |
| 0.5994 | 0.5947 | 9/10 | 10 (0.0107) | 0.5992 | 0.5938 | 10/10 | 10 (0.0010) | |
| 0.6065 | 0.5792 | 10/10 | 10 (0.0010) | 0.6108 | 0.5941 | 10/10 | 10 (0.0010) | |
| 0.6349 | 0.5450 | 7/10 | 9 (0.0107) | 0.6352 | 0.5677 | 10/10 | 9 (0.0107) | |
Significant Gene–Environment interactions along with main effects
| Gene | ^Main effects | SNP ∗ environment | OR | Lower95ci | Upper95ci | p value † |
|---|---|---|---|---|---|---|
| MG | 0.512 | 0.36 | 0.728 | 0.0002 | ||
| VNV | 0.604 | 0.391 | 0.932 | 0.023 | ||
| BMI | 1.126 | 1.081 | 1.174 | < 0.001 | ||
| TCF7L2 ∗ BMI | 1.054 | 0.998 | 1.112 | 0.057 | ||
| MG | 0.347 | 0.221 | 0.546 | < 0.001 | ||
| VNV | 0.585 | 0.334 | 1.025 | 0.061 | ||
| Smoking | 0.559 | 0.284 | 1.101 | 0.093 | ||
| BMI | 1.114 | 1.058 | 1.173 | < 0.001 | ||
| IGF2BP2 ∗ BMI | 0.036 | 0.023 | 1.595 | 0.111 | ||
| BMI | 1.15 | 1.056 | 1.251 | 0.001 | ||
| MG | 0.577 | 0.409 | 0.814 | 0.002 | ||
| VNV | 0.534 | 0.348 | 0.82 | 0.004 | ||
| BMI | 1.14 | 1.094 | 1.188 | < 0.001 | ||
| CDKAL1 ∗ MG | 0.632 | 0.404 | 0.987 | 0.044 | ||
| CDKAL1 ∗ ALCOHOL | 1.701 | 0.952 | 3.04 | 0.073 | ||
| MG | 0.399 | 0.15 | 1.065 | 0.067 | ||
| VNV | 0.321 | 0.098 | 1.05 | 0.06 | ||
| MG | 0.42 | 0.276 | 0.639 | < 0.001 | ||
| BMI | 1.151 | 1.095 | 1.21 | < 0.001 | ||
| MG | 0.429 | 0.326 | 0.565 | < 0.001 | ||
| VNV | 0.699 | 0.495 | 0.986 | 0.041 | ||
| BMI | 1.15 | 1.11 | 1.18 | < 0.0001 | ||
| MG | 0.445 | 0.326 | 0.607 | < 0.001 | ||
| Smoking | 0.601 | 0.377 | 0.956 | 0.031 | ||
| BMI | 1.147 | 1.106 | 1.19 | < 0.001 | ||
| CAPN10 ∗ smoking | 4.954 | 0.928 | 26.442 | 0.061 | ||
| BMI | 1.177 | 1.045 | 1.325 | 0.007 |
† 5% and 10% significance was considered.
Fig. 1Distribution of risk alleles of T2DM cases and controls.
Fig. 2Line plot showing the values of odds ratios and 95% confidence intervals (CI) from logistic regression analysis of the number of risk alleles among the T2DM cases and controls.
Fig. 3Discriminant analysis using receiver operator curve (ROC) based on the risk allele categories among T2DM cases and controls.
Two-sampled proportion Z test for T2DM cases and controls for the eight significant combinations. Blue color indicates — protective; red color indicates susceptible to T2DM based on their frequencies among cases and controls.
*5% and 10% significance was considered.